Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J Ko

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
JIMD Reports|January 13, 2023
Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) studyAmy Dickey, Kristen Wheeden, Desiree Lyon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 30, 2021
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION studyPaolo Ventura, Herbert L Bonkovsky, Laurent Gouya, et al.
The New England Journal of Medicine|June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaManisha Balwani, Eliane Sardh, Paolo Ventura, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
JIMD Reports|January 13, 2023
Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) studyAmy Dickey, Kristen Wheeden, Desiree Lyon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 30, 2021
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION studyPaolo Ventura, Herbert L Bonkovsky, Laurent Gouya, et al.
The New England Journal of Medicine|June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaManisha Balwani, Eliane Sardh, Paolo Ventura, et al.
Pageof 2